

* DISEASE REDUCTION [%]
DISEASE ACTIVITY [%]
400
300
200
100
0
*-27.9
*33.58
*53.55
*96.75
*96.02
VEHICLE
3mg/kg
1mg/kg
0.3mg/kg
0.1mg/kg
SHAM
CELL CEPT 300mg/kg

FIG. 1A



* DISEASE REDUCTION [%]
DISEASE ACTIVITY [%]
400
300
200
100
0
*-27.9
*33.58
*53.55
*96.75
*96.02
VEHICLE
CPD. B (3mg/kg)
CPD. B (1mg/kg)
CPD. B (0.3mg/kg)
CPD. B (0.1mg/kg)
MMF CELL CEPT 300mg/kg
SHAM

FIG. 1B



VEHICLE
CPD B. 3mg/kg
CPD B. 1mg/kg
CPD B. 0.3mg/kg
CPD B. 0.1mg/kg
CELL CEPT 300mg/kg
MEAN PROTEIN/ CREATININ RATIO IN URINE
100
80
60
40
20
0
0
2
4
6
8
10
WEEKS AFTER APPLICATION OF ADV-IFNα
*** *** *** *** *** *** * * *** ***

FIG. 2



CONTROL
VEHICLE
MTX 0.1mg/kg
CPD A. 0.3mg/kg
CPD A. 1mg/kg
CPD A. 3mg/kg
CPD A. 10mg/kg
CPD A. 30mg/kg
0.340
0.330
0.320
0.310
0.300
0.290
0.280
0.260
0.260
MEAN ± SE ANKEL DIAMETER OVER TIME (IN)
DAY 09
DAY 10
DAY 11
DAY 12
DAY 13
DAY 14
DAY 15
DAY 16
STUDY DAY

FIG. 3



NAÏVE (*d25-34)
VEHICLE 2 DISEASE CONTROL
CPD. A 1mg/Kg (*d23-34)
CPD. A 3mg/Kg (*d23-34)
CPD. A 10mg/Kg (*d23-34)
CPD. A 30mg/Kg (*d23-34)
MTX (0.5mg/kg (*d-23-34
MEAN ± SE CLINICAL ARTHRITIS SCORE (SCORED 0-5)
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34
ARTHRITIS DAY

FIG. 4



EVANS'S
BLUE
EXTRAVASATION
ng DYE/
mg TISSUE
(MEAN ± SEM)
40
30
20
10
0
41%
**
73.4%
**
93.8%
SHAM
VEHICLE
3.95
19.8
39.5
CPD B. mg/kg p.o.

FIG. 5



EX-VIVO
αIgM-INDUCED
CD69 UP
REGULATION
(% OF INHIBITION)
120
80
40
0
***
#38.3%
***
#85.8%
***
#90.2%
VEHICLE
1.19
mg/kg
3.96
mg/kg
11.9
mg/kg
ONE-WAY ANOVA
**** P<0.0001 VERSUS VEHICLE CYCLODEXTRIN
#% OF INHIBITION

FIG. 6